-

Crescita Announces Exclusive Canadian Distribution Agreement with Obagi Cosmeceuticals LLC

LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita”), a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has entered into a distribution agreement with Obagi Cosmeceuticals LLC (“Obagi”) for the exclusive rights to promote, distribute and sell the Obagi Medical® product line in Canada.

The Obagi Medical line provides transformational skincare products formulated to minimize signs of aging, address dark spots, hyperpigmentation, fine lines and wrinkles and to protect and enhance skin tone and texture. Crescita will promote and sell the products nationwide through its existing network.

Serge Verreault, President and Chief Executive Officer of Crescita, commented, “We are pleased to welcome Obagi as our newest distribution partner. We believe this partnership is a logical next step in the expansion of our product portfolio in the growing medical aesthetics market and are excited about bringing these premium, innovative and effective products back to Canadian consumers.”

Jaime Castle, President & Chief Executive Officer of Obagi Cosmeceuticals, LLC, commented, “We are thrilled to initiate the relaunch of the Obagi® brand to Canadian consumers alongside our partner, Crescita Therapeutics. Obagi’s innovative products & global expansion strategy are perfectly matched with Crescita’s proven reputation within the Canadian aesthetic space. We look forward to a long & productive partnership together.”

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. In addition, we own multiple proprietary transdermal delivery platforms that support the development of patented formulations that facilitate the delivery of active ingredients into or through the skin.

About Obagi Cosmeceuticals, LLC.

Obagi is an advanced global skin care company dedicated to providing advanced, clinically proven skin care treatments for all skin types. With a 30-year legacy and commitment to diversity and inclusion in all aspects of its business – from its corporate culture to product development – Obagi has pioneered a number of skin care advances, including being the first skin care brand to design its clinical research covering all six skin types across the Fitzpatrick skin spectrum. Through an extensive network of distributors, partners and physician offices in over 90 countries around the world, the company provides more than 100 Obagi products to brighten, nourish, protect, and enhance skin tone and texture.

Contacts

Crescita Therapeutics
Investor Relations
Linda Kisa, CPA, CA
Email: lkisa@crescitatx.com

Crescita Therapeutics

TSX:CTX

Release Versions

Contacts

Crescita Therapeutics
Investor Relations
Linda Kisa, CPA, CA
Email: lkisa@crescitatx.com

More News From Crescita Therapeutics

Crescita Reports Q4 and Fiscal 2024 Results

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2024 (“Q4-2024” and “F2024”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued b...

Crescita Reports Third Quarter 2024 Results

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the third quarter ended September 30, 2024 (“Q3-2024”). All amounts presented in this press release are in thousands of Canadian dollars (“CAD”) unless otherwise noted and are in accordance with International Financial Reporting Standards (“IFRS”) as issued by...

Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that the Toronto Stock Exchange (the “TSX”) has approved the Company’s proposed normal course issuer bid (“NCIB”) to purchase up to a maximum of 1,478,854 common shares (“Common Shares”) for cancellation, representing approximately 10% of its public float as of September 16, 2024, as a...
Back to Newsroom